Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes
Results from the thrombolysis in myocardial infarction (TIMI) 11B and efficacy and safety of subcutaneous enoxaparin in Non–Q-Wave coronary events (ESSENCE) studies
Nick R. Bijsterveld, MD*,
Ron J. G. Peters, MD*,*,
Sabina A. Murphy, MPH ,
Peter J. L. M. Bernink, MD ,
Jan G. P. Tijssen, PhD*,
Marc Cohen, MD, FACC TIMI 11B/ESSENCE Study Groups
* Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
TIMI Data Coordinating Center, Boston, Massachusetts, USA
Department of Cardiology, Martini Hospital, Groningen, The Netherlands
Department of Cardiology, Newark Beth Israel Medical Center, Newark, New Jersey, USA
View larger version (14K):
[in a new window]
|
Figure 1 Cumulative incidence for the occurrence of death, myocardial infarction, or urgent revascularization by treatment group during the first seven days after treatment discontinuation. LongEnox = long-term out-hospital continuation of enoxaparin treatment; ShortEnox = short-term in-hospital enoxaparin treatment; UFH = unfractionated heparin.
|
|
View larger version (26K):
[in a new window]
|
Figure 2 Hazard of death, myocardial infarction, or urgent revascularization per day during the day before (–1) and days (1 to 7) after discontinuation of UFH or short-term enoxaparin. Note: by definition, day –1 (i.e., 24 h before treatment discontinuation) does not include patients who died or underwent an urgent revascularization. Abbreviations as in Figure 1.
|
|
View larger version (29K):
[in a new window]
|
Figure 3 The Thrombolysis In Myocardial Infarction (TIMI) risk factor distribution in patients with early rebound, that is, occurrence of a primary end point event within 24 h after discontinuation of treatment. Abbreviations as in Figure 1.
|
|
|
